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Abstract: Vascular invasion has been identified as an informative
risk factor for relapse in stage I testicular nonseminomas, used to
tailor treatment. We investigated interobserver agreement in
vascular invasion reporting and studied the potential additional
value of immunohistochemistry for vascular markers for pre-
dicting relapse. Patients (n= 52) with stage I testicular non-
seminomas undergoing surveillance (1993-2006) were included
(median follow-up of 66 mo). Two formalin-fixed paraffin-
embedded blocks with > 1 cm2 tissue and tumor/normal paren-
chyma interface were stained with hematoxylin and eosin and
CD31, FVIII, and D2-40. Slides were assessed by 3 independent
testicular germ cell tumor-dedicated pathologists, and agreement
was assessed using Cohen κ statistic. Sensitivity, specificity, and
accuracy of vascular invasion scoring in predicting relapse
were calculated. Agreement among testicular germ cell tumor-
dedicated pathologists was moderate (κ= 0.49 to 0.54), as was
performance in predicting disease relapse (particularly, specificity
of 86%). Immunohistochemistry increased overall sensitivity
(71%), but decreased specificity (71%) in predicting relapse. All
patients (n= 8) with both blood and lymphatic vascular invasion
developed a relapse. In multivariable analysis (including age,
tumor size, rete testis invasion, and serum tumor markers), only
vascular invasion had an independent impact in predicting re-
lapse. Assessment of vascular invasion by testicular germ cell
tumor-dedicated pathologists is good and is clinically mean-
ingful, predicting disease relapse. Immunohistochemistry for
vascular markers improves sensitivity of detecting disease relapse
and allows for the identification of high-risk patients with both
blood and lymphatic vascular invasion simultaneously, poten-
tially of interest for tailored chemotherapy.
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Testicular germ cell tumors are the most common neo-plasms among young-adult Caucasian men, and in-
cidence has been rising in most countries.1 They represent,
however, one of the most curable solid neoplasms, and
current guidelines include the option of assigning both
seminoma and nonseminoma stage I patients to active
surveillance, a strategy that is being increasingly adopted
as the preferred management modality.2 Indeed, about
70% to 85% of stage I testicular germ cell tumor patients
(72% to 75% specifically for stage I nonseminoma patients
according to published series) are cured with orchiectomy
alone.3–5 Nevertheless, a group of patients ultimately de-
velop disease relapse, particularly nonseminoma patients,
and especially in the first 2 years after orchiectomy, im-
plying additional treatment.6 Hence, biomarkers are ur-
gently needed that can accurately predict which patients
are going to experience relapse, so that treatment strat-
egies can be individually tailored: avoiding unnecessary
overtreatment of low-risk patients who can be maintained
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in surveillance, sparing them from the deleterious long-
term side effects of cytotoxic therapies, and allowing for a
better selection of patients who really benefit from ad-
juvant treatment after orchiectomy, so as to avoid disease
relapse and associated complications.7,8
Vascular invasion has been pointed out as such a
marker in various studies, an idea first suggested by Ragha-
van et al9 and Peckam et al.10 The presence of vascular in-
vasion is associated with poor prognosis, relapse, and
metastases, particularly in nonseminomas.5,11–25 The rele-
vance of vascular invasion in testicular germ cell tumors is
illustrated by its inclusion in the TNM staging system, re-
sulting in a pT2.26 Given this clinical importance, strict cri-
teria for establishing the diagnosis of vascular invasion are
recommended by expert panels, as some representations may
result in overdiagnosis and, hence, possible overtreatment of
patients.2,24,27 However, testicular germ cell tumors are
overall infrequent and, at the same time, are among the most
diverse tumors in human pathology. This heterogeneity is
problematic, as pathologists may see few cases a year in their
routine, leaving room for disagreements in clinically relevant
areas, which can lead to overtreatment.28,29 Studies have re-
ported discrepancies in the pathologic assessment of testicular
germ cell tumors between peripheral, general pathology de-
partments, and centers with more expertise and dedication to
these tumors. In fact, the most significant disagreement be-
tween these kinds of centers relates to vascular invasion in-
terpretation (especially in nonseminoma cases), putting in
evidence that the reproducibility on reporting this parameter
by pathologists is far from ideal.30–32
In current guidelines, there is no formal indication
for staining with vascular markers in order to aid the de-
tection of vascular invasion, nor is it mandatory to discrim-
inate the type of vessel invasion present in a tumor (either
lymph vessel invasion, blood vessel invasion, or both).24,33
However, studies dealing with this matter in testicular germ
cell tumors are lacking, and this was stated as the reason for
not establishing a recommendation on the topic in the
last International Society of Urological Pathology (ISUP)
Testicular Cancer Consultation Cancer Recommendations
meeting.24
In this work, we aim to assess the inter-rater agreement
between testicular germ cell tumor-dedicated pathologists in
reporting vascular invasion. We also aim to determine the
clinical value of adding immunohistochemistry for vascular
markers to routine hematoxylin and eosin (H&E) when
carrying out this assessment for ultimately predicting disease
relapse in a cohort of stage I nonseminoma patients, all un-
dergoing surveillance. Finally, we intend to confirm the
prognostic role of vascular invasion, namely its impact on
relapse-free survival, and to explore the additional value of
knowing the type of vessel invaded by the tumor.
MATERIALS AND METHODS
Patients and Samples
All patients consecutively diagnosed with stage I
testicular nonseminoma between 1993 and 2006 were
retrospectively queried from our database (which includes
patients submitted to orchiectomy in various centers of the
Netherlands). From these, only patients who underwent a
surveillance strategy after orchiectomy were included in
the study (ie, all patients undergoing adjuvant treatments
were excluded). Clinical charts of each patient were re-
viewed by an investigator blinded to the results of the
analysis. Variables collected included the following: age
and serum tumor markers at diagnosis; tumor histologic
subtype, laterality, size, multifocality, presence of vascular
invasion, and rete testis invasion (according to the original
pathology report of the respective center); therapies used
for relapses (surgery and chemotherapy); type and top-
ography of relapses; and dates of birth, diagnosis, relapse,
death, and last follow-up. Disease relapse was defined as
“early” or “late,” as defined elsewhere.34 Patients without
the required clinical information were excluded.
Orchiectomy samples were fixed overnight in 10%
buffered formalin and paraffin-embedded. As regards tis-
sue sample selection, it was determined that all cases
should have at least 2 blocks with tumor representation
available; that at least one of these blocks (preferably
both) contained the interface between tumor and adjacent
testicular parenchyma; and that each block contained at
least 1 cm2 of tissue. Accompanying H&E slides were
scanned for selecting sections fulfilling these criteria. Four
serial 4-µm sections were then ordered from samples
complying to these criteria, one for H&E staining and the
remaining for immunohistochemistry.
Immunohistochemistry
Immunohistochemistry was performed using the pol-
ymer detection method. After deparaffinization, antigen
retrieval was performed in a pressure cooker after pre-
treatment with TRIS-EDTA at pH 9. Endogenous perox-
idase activity was blocked by 3% hydrogen peroxide.
Sections were then blocked for endogenous biotin with the
Vector blocking kit. Slides were incubated overnight with
anti-D2-40 antibody (1:100, clone D2-40; Dako, Glostrup,
Denmark), anti-CD31 antibody (1:50, clone JC70A; Dako),
and anti-factor 8 antibody (1:8000, polyclonal; Dako).
Antigen-antibody complexes were detected using the Vector
Avidin Biotin HRP, and visualization was performed with
3,3′-Diaminobenzidine and hydrogen peroxide. Hematox-
ylin was used for counterstaining for 3 minutes. Vessels of
the tissue were used as (internal) positive control.
Vascular Invasion Assessment
Vascular invasion was assessed on H&E slides
(without access to immunostaining) by 3 independent
testicular germ cell tumor-dedicated pathologists (Klaas
van Kerckhoven, J.L., and a renowned expert, W.O.). The
exact same set of slides was presented to each observer,
and their assessment was independent and blinded to any
clinicopathologic data. All pathologists rated vascular
invasion as a dichotomic variable: “without vascular in-
vasion” versus “with vascular invasion.” In a later phase,
discordant cases among the 3 testicular germ cell tumor-
dedicated pathologists were further discussed in group
under the microscope until a consensus was met.
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Immunohistochemistry evaluation of the cases was
performed by J.W.O., again independently and blinded to
any clinicopathologic data. Besides scoring vascular invasion
as “absent” or “present,” the type of vessel composing the
vascular invasion was also discriminated: lymph vessel, blood
vessel, or presence of both. The antibody panel was used as
indicated: D2-40 for specifically staining lymph vessel endo-
thelium; CD31 and Factor VIII both for staining blood vessel
endothelium, and also for weakly staining lymph vessels.
Statistical Analysis
The data were tabulated using Microsoft Excel 2016
and analyzed using IBM SPSS Statistics version 24. Percen-
tages were calculated on the basis of the number of cases with
available data. Cohen κ was run to determine whether there
was agreement between 2 pathologists’ judgment on whether
vascular invasion was present on the available H&E slides.
The level of agreement was categorized as in the guidelines by
Landis and Koch.35 Associations between categorical varia-
bles were assessed using χ2 (with continuity correction).
Distribution of continuous variables among groups was
compared using the nonparametric Mann-Whitney U test.
Sensitivity, specificity, positive predictive value, negative
predictive value, and accuracy of vascular invasion assess-
ment on predicting relapse was calculated. Survival analyses
were computed with Kaplan-Meier estimator and log-rank
test. Hazard ratios and respective 95% confidence intervals
were estimated using Cox regression models. A P-value equal
or inferior to 0.05 was considered statistically significant.
RESULTS
Cohort Characterization
A total of 52 patients met the study criteria and were
included. Detailed clinicopathologic features of the patients are
depicted in Table 1. Median follow-up time was 66 months
(interquartile range: 40 to 93mo). Median patients’ age at
diagnosis was 31 years (interquartile range: 24 to 35 y). Seven
tumors showed pure histology (5 pure embryonal carcinomas
and 2 pure postpubertal-type teratomas), and 45 (86.6%) were
mixed tumors. Thirty-one (59.6%) patients experienced disease
relapse, only 3 of them corresponding to late relapses (at 65,
48, and just over 24mo). One of the patients with late relapse
died from disease at 63 months (with metastatic dissemination
to liver, lung, and retroperitoneal lymph nodes), and another
one died because of an intercurrence unrelated to his disease at
31 months. Patients with relapse received chemotherapy, and
additional retroperitoneal lymph node dissection in the case of
5 patients. Two of the patients developed a second relapse, for
which they received further treatment. Detailed information
about histologic components and treatment of relapses is
depicted in Supplemental Digital Content 1 (http://links.lww.
com/PAS/A834).
Vascular invasion, as considered in the final path-
ology report, was significantly associated with relapse
(P< 0.001). No significant association was depicted be-
tween any other variable (patients’ age, elevation of serum
tumor markers, histology, rete testis invasion, or tumor
size) and the event of disease relapse. In our cohort,
patients with the presence of embryonal carcinoma did not
show a significantly worse relapse-free survival compared
with patients without the presence of embryonal carcino-
ma. Moreover, no significant association was depicted
between tumor size and rete testis invasion, between rete
testis invasion and vascular invasion, or between tumor
size and vascular invasion.
Interobserver Agreement in Vascular Invasion
Scoring on H&E
A moderate agreement was always found with re-
gard to the scoring of vascular invasion by the 3 testicular
TABLE 1. Clinicopathologic Features of Stage I Nonseminoma
Patients
Variables
Patient Cohort (N= 52),
n/N (%)
Age (median, interquartile range) (y) 31 (24-35)
Laterality
Right 21/52 (40.4)
Left 31/52 (59.6)
Preoperative serum tumor markers
Within normal range 20/52 (38.5)
Elevated 32/52 (61.5)
Histologic subtypes*
Pure embryonal carcinoma 5/52 (9.6)
Pure postpubertal-type teratoma 2/52 (3.8)
Mixed tumor, without seminoma 21/52 (40.4)
Mixed tumor, with seminoma
(combined tumor)
24/52 (46.2)
Multifocality*
Absent 50/52 (96.2)
Present 2/52 (3.8)
Largest tumor size (median, interquartile
range)* (cm)
3.5 (2.5-5.4)
Rete testis invasion*
Absent 30/42 (71.4)
Present, stromal 9/42 (21.4)
Only pagetoid spread of GCNIS 3/42 (7.1)
Vascular invasion*
Absent 25/50 (50.0)
Present 25/50 (50.0)
Relapse
No 21/52 (40.4)
Yes 31/52 (59.6)
Type of relapse
Early 28/31 (90.3)
Late 3/31 (9.7)
Site of relapse
Only serum markers 6/31 (19.4)
Serum markers+PAoLN 14/31 (45.2)
Only PAoLN 4/31 (12.9)
Only lung 2/31 (6.5)
Serum markers+lung+PAoLN 4/31 (12.9)
Serum markers+liver+lung+PAoLN 1/31 (3.2)
Treatment performed for relapses
Only chemotherapy 26/31 (83.9)
Chemotherapy+RPLND 5/31 (16.1)
Vital status at last follow-up
A-NED 50/52 (96.2)
D-NED 1/52 (1.9)
DFD 1/52 (1.9)
*According to the original pathology report.
A-NED indicates alive with no evidence of disease; DFD, died from disease;
D-NED, died with no evidence of disease; GCNIS, germ cell neoplasia in situ;
PAoLN, para-aortic lymph nodes; RPLND, retroperitoneal lymph node dissection.
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germ cell tumor-dedicated pathologists (κ= 0.49, 0.50,
0.54, P< 0.001 for all). The pairs of observers were in
agreement in 75% to 80% of the times (Table 2).
Performance of Vascular Invasion Scoring in
Predicting Disease Relapse
The independent H&E assessment of vascular in-
vasion by the 3 testicular germ cell tumor-dedicated
pathologists always associated with disease relapse
(P= 0.001, 0.009, 0.012). When judging the consensus of
the 3 testicular germ cell tumor-dedicated pathologists (on
H&E only) as the “standard,” the following performance
on predicting relapse was achieved: sensitivity= 61.3%,
specificity= 85.7%, positive predictive value= 86.4%,
negative predictive value= 60.0%, and accuracy= 71.2%
(Table 3). Of the 22 cases wherein H&E assessment
determined there was vascular invasion, 19 (86.4%) indeed
developed relapse. However, 12 patients in whom vascular
invasion was reported as absent (40.0%) developed relapse
(Table 4).
By adding immunohistochemistry for the afore-
mentioned vascular markers, sensitivity in predicting dis-
ease relapse was increased (71.0%), and specificity was
decreased (71.4%), maintaining the same accuracy
(Table 3). Immunohistochemistry assessment upgraded 8
cases of absent vascular invasion on H&E to presence of
vascular invasion, and 3 of these patients developed
relapse. Moreover, it downgraded 2 cases of presence of
vascular invasion on H&E to absence of vascular
invasion, and these patients did not develop relapse.
Immunohistochemistry allowed for determination of
15 patients with lymph vessel invasion only, of whom 12
developed relapse (80.0%); 5 patients showing blood vessel
invasion only, of whom 2 developed relapse (40.0%; late
relapse in both cases); and 8 patients with both lymph vessel
and blood vessel invasion evidence, all of them showing
disease relapse (Table 4). The vascular-invasive histotype
was embryonal carcinoma in all cases except 2, showing
seminoma in lymph vessels. Of the 13 patients who
exhibited blood vessel invasion, 3 (23.1%) showed relapse
in a visceral organ; of the 23 patients who exhibited lymph
vessel invasion, 15 (65.2%) suffered relapse in lymph nodes.
One of the patients with a second relapse showed both
lymph vessel and blood vessel invasion.
Illustrative examples of vascular invasion patterns
detected on immunohistochemistry, but missed on H&E,
and also a common vascular invasion mimicker, are de-
picted in Figures 1 and 2, respectively.
Survival Analysis
Patients classified as having a vascular invasion on
the H&E consensus assessment showed significantly worse
relapse-free survival when compared with patients without
vascular invasion (P= 0.001, Fig. 3). In multivariable
analysis (including age, tumor size, rete testis invasion,
and serum tumor markers), vascular invasion showed an
independent impact in predicting relapse (hazard ratio,
3.163; 95% confidence interval, 1.31-7.63).
DISCUSSION
In the last decades, much effort has been put toward
better stratifying stage I nonseminoma patients according to
their risk of relapse. Specifically, the aim is to better dis-
criminate those patients who truly benefit from further
treatment after orchiectomy from those who can safely
follow a surveillance protocol.6,37,38 The most consistent
histological parameter to predict disease recurrence in clin-
ical stage I nonseminoma has been vascular invasion,11–23
TABLE 2. Interobserver Agreement in Vascular Invasion
Scoring
Testicular Germ Cell Tumor-dedicated Pathologists’ Assessment
of Vascular Invasion
Absent Present
Agreement: Cohen κ= 0.54
(P< 0.001)
Pathologist 3
Pathologist 1
Absent 23 4
Present 8 17
Agreement: Cohen κ= 0.50
(P< 0.001)
Pathologist 2
Pathologist 1
Absent 22 5
Present 8 17
Agreement: Cohen κ= 0.49
(P< 0.001)
Pathologist 2
Pathologist 3
Absent 24 7
Present 6 15
TABLE 3. Performance Parameters for Predicting Disease
Relapse on the Basis of Vascular Invasion Scoring
Vascular
Invasion
Scoring
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
Accuracy
(%)
H&E (consensus) 61.3 85.7 86.4 60.0 71.2
Immunohisto-
chemistry
(D2-40+FVIII
+CD31)
71.0 71.4 78.6 62.5 71.2
NPV indicates negative predictive value; PPV, positive predictive value.
TABLE 4. Association Between Vascular Invasion Scoring, Type
of Vessel With Invasion, and Relapse
Vascular Invasion Scoring No Relapse (n) Relapse (n)
H&E consensus
Without VI 18 12
With VI 3 19
IHC
Without VI 15 9
With VI 6 22
IHC showing LVI only 3 12
IHC showing BVI only 3 2
IHC showing LVI+BVI 0 8
BVI indicates blood vessel invasion; IHC, immunohistochemistry; LVI, lymph
vessel invasion; VI, vascular invasion.
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and our study was no exception, with vascular invasion
being the only variable with significant impact on relapse-
free survival after multivariable analysis.39,40 However,
more factors apart from vascular invasion have been col-
lected that demonstrate an impact in determining disease
relapse, namely the amount of embryonal carcinoma.17 The
FIGURE 1. Illustrative examples of vascular invasion detected on immunohistochemistry that were missed on H&E. A–D, A case of
blood vessel invasion by embryonal carcinoma (left, top to bottom: H&E, D2-40, CD31, and FVIII). E–H, A case of lymph vessel
invasion by embryonal carcinoma (right, top to bottom: H&E, D2-40, CD31, and FVIII). Part of this figure was also included by the
authors in Moch et al.36
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latter has been gaining robustness as a prognostic factor in
nonseminoma patients,41,42 and it is biologically plausible
that this is (at least partially) associated with vascular in-
vasion itself. Despite that no recommendation is made to
report the type of tumor responsible for vascular invasion in
mixed tumors,24 our study demonstrates that almost all
positive cases related to the embryonal carcinoma compo-
nent (fitting with the model that metastatic cells are typically
the cancer stem cells).36,43,44
Studies have shown that the global agreement in
testicular pathology assessment among testicular germ cell
tumor-dedicated pathologists is good. However, some
disagreements still persist in areas such as staging and
reporting of histologic subtypes.45 Moreover, studies have
demonstrated the impact of centralized review of testicular
germ cell tumor cases by experienced centers, with changes
in the original report of up to 28%, alterations in prognosis
assessment in 9% of patients, and a predicted impact on
therapy of 6.5% of patients.32 The most common reason
for disagreement in nonseminomas was the assessment of
vascular invasion.31 Another study demonstrated only a
slight concordance in vascular invasion assessment be-
tween the original and reviewed reports (κ= 0.16), with
only the revised scoring associating with nodal status at
retroperitoneal lymph node dissection.30 Our work is in
line with these studies, with the agreement in vascular
invasion scoring among 3 testicular germ cell tumor-
dedicated pathologists being good. Importantly, it was
also clinically relevant, associating with relapse-free sur-
vival (including in multivariable analysis) and showing a
good performance (accuracy of 71.2%) in predicting dis-
ease relapse on 2 available H&E slides only. This under-
scores the consistency and clinical value of vascular
invasion assessment by pathologists with experience in
the field of germ cell cancer. Our results support the
FIGURE 2. Intratubular embryonal carcinoma as a mimicker of
vascular invasion. Note the presence of necrosis and absence of
clear staining for vascular markers (A–D: H&E, D2-40, CD31,
and FVIII). Part of this figure was also included by the authors in
Moch et al.36
FIGURE 3. Relapse-free survival according to vascular invasion
scoring. Tick marks in survival curves represent censored subjects
over time.
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recommendation for medical oncologists to request,
whenever possible, a review of testicular germ cell tumor
cases by an experienced pathologist seeing a minimum of
30 cases a year.2
The assessment of vascular invasion in most centers is
routinely performed on the H&E slide. Various representa-
tions can mimic vascular invasion and lead to overdiagnosis.
One of such is the presence of histiocytes inside vessels and
also intratubular nonseminoma (which almost always corre-
sponds to intratubular embryonal carcinoma, Fig. 2).24
Accurate recognition of true vascular invasion may be
hampered by poor fixation and related smear artifacts.46,47
Scarce sampling of fragments representing the interface with
adjacent testicular parenchyma and albuginea is also a
limiting factor, as most of the vascular invasion is found in
these areas.24 This was the reason for including interface
representation as an inclusion criterion of our study. Vascular
invasion in testicular germ cell tumors is incorporated in the
TNM staging system, representing pT2 disease (instead of
pT1) in case of a positive finding, and subsequently, stage IB
(instead of stage IA). Hence, pathologists are advised to
follow strict criteria for defining it: tumor occupying a
vascular structure delineated by flattened endothelial cells, in
a cluster not conforming to the exact shape of the lumina;
presence of accompanying fibrinous thrombosis, mural
attachment, or reendothelialization; lack of obvious smear
artifacts in nearby structures (such as lying on the tunical
surface); and clusters that are more cohesive or smooth-
edged.24,47 Experienced testicular germ cell tumor-dedicated
pathologists are naturally aware of these criteria and follow
them rigorously, and only score vascular invasion as present
on H&E when absolutely sure, due to the known risk of
overtreatment in case of a false-positive result (following the
last ISUP recommendations).24 We hypothesize that this is
the reason for the high specificity of H&E in predicting
relapse. In contrast, most disagreements among testicular
germ cell tumor-dedicated pathologists in our study occurred
when the true expert (with decades of expertise) reported
vascular invasion as present, whereas the 2 less experienced
observers of the 3 considered it absent. We believe that
these discordances in scoring might be due to difficult
and challenging cases on H&E, only recognized by an
experienced pathologist.
There is, at the moment, no formal recommendation
for performing immunohistochemistry studies for aiding
in vascular invasion determination nor for the need to
discriminate lymph vessel from blood vessel invasion.24
Few studies have assessed the latter, and it remains in-
conclusive whether discriminating among these might
have additional value; one study has shown that only
lymph vessel invasion associated with prognosis (meta-
stases at diagnosis),48 while another paper reported the
opposite scenario.49 Furthermore, a small pilot study on
24 testicular germ cell tumors showed that ERG
immunohistochemistry could be of value in confirming
vascular invasion, despite showing limited clinical impact
in that small and heterogenous cohort of patients.50
We believe our work further extends these indications
on the usefulness of immunohistochemistry. We have
systematically performed immunohistochemistry for D2-
40, Factor VIII, and CD31,51 and staining for these 3
markers resulted in increased sensitivity in predicting dis-
ease relapse (71.0%), although at the expense of lower
specificity (71.4%), maintaining the same accuracy. The
slight decrease in specificity for predicting relapse parallels
the increase in sensitivity, and may result from misinter-
pretation of the staining due to artifacts. In practice, this
allowed for the identification of 8 more cases of vascular
invasion not depicted on H&E, which showed clinical
relevance for 3 of these patients, who ended up developing
relapse. Two major tumor patterns emerged for explaining
this discrepancy: the first one which exhibited vessels
completely filled by solid masses of tumor cells without
any discernable lumen; the second one which concerned
small lymphatic vessels containing individual loose tumor
cells, very hard to detect on H&E without the aid of D2-
40. In addition, immunohistochemistry avoided over-
scoring of vascular invasion in 2 cases when compared
with H&E interpretation, again with clinical relevance, as
these patients did not develop relapse.
Moreover, immunohistochemistry allowed for dis-
criminating lymph vessel from blood vessel invasion, the
former being more frequent than the latter. This is bio-
logically expected given the predominantly lymphatic route
of metastases from testicular nonseminomas. We have iden-
tified 2 main patterns of blood vessel invasion: either large
vessels with thickened walls, or vessels with faint, almost
imperceptible walls, easily overlooked in H&E staining, but
clearly highlighted by CD31/Factor VIII. Importantly, it is
noteworthy that all 8 cases presenting both with lymph vessel
and blood vessel invasion experienced disease recurrence.
This included, in fact, 1 patient who experienced a second
relapse. This 100% accuracy in predicting recurrence when
lymph vessel and blood vessel invasions are present in the
same tumor may mean that these patients are better treated
actively, instead of being referred for a surveillance strategy.
The finding of these “double-vascular invasion” patients with
a very high risk of recurrence has not been reported before, to
the best of our knowledge.
One of the limitations of our work is its retrospective
nature and the relatively small size of our cohort. More-
over, the amount of embryonal carcinoma in the tumor is
lacking in our study, because it was not consistently re-
ported in the original report. Futhermore, as stated above,
we only examined 2 blocks of each case; hence, a true
assessment of the totality of the tumors was not possible.
Nevertheless, when looking at all cases considered not to
display vascular invasion in the original report with access
to all tumor material, 6 of them still showed vascular in-
vasion in the 2 random blocks reviewed, putting in evi-
dence the value of a centralized review even with access to
limited material. In addition, our study has the strength of
including a real “clean” cohort of only nonseminoma
patients, all of whom had stage I disease and were un-
dergoing a surveillance strategy. This way, we believe we
have minimized the effect of confounder variables to the
minimum and trust our results really reflect the value of
vascular invasion scoring in predicting disease relapse.
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Moreover, patients were followed-up in different in-
stitutions, showing that the findings of this study are
consistent in a heterogeneous population, and not due to a
selection bias of only one niche of patients from a single
center. Moreover, in this work, we verified the assump-
tions of the Cohen κ test, so that it could be reliably used
as a measure of interobserver agreement above the one
expected just by chance.
All in all, we confirm that vascular invasion is indeed a
major risk factor in stage I nonseminoma patients for pre-
dicting relapse, and that our scoring by testicular germ cell
tumor-dedicated pathologists was accurate, consistent, and
clinically relevant, even with access to 2 H&E slides only,
comparing with the performance reported by pathology ref-
eree panels. However, the interobserver agreement in scoring
can be improved. The use of immunohistochemistry for this
purpose, scarcely addressed in the literature and still a matter
of debate due to insufficient data, shows additional value in
detecting vascular invasion, with higher sensitivity in pre-
dicting relapse. We believe that, for the time being, careful
examination of the tumor front and interface with paren-
chyma should be pursued, and, whenever there is a suspicious
image of vascular invasion, the immunohistochemistry panel
composed of CD31, Factor VIII, and D2-40 should definitely
be ordered to confirm the findings (Supplemental Digital
Content 2, http://links.lww.com/PAS/A835). However, re-
markably, performing immunohistochemistry for these
markers also allows for the identification of “lymph vessel
plus blood vessel invasion” patients, which evidenced relapse
in 100% of cases. This novel finding might allow discrim-
inating a subgroup of “very high-risk” patients, who should
probably be selected for further adjuvant treatment after or-
chiectomy. Hence, we believe our findings on additional use
of immunohistochemistry might shed some light on the topic
and potentiate future recommendations on it.
In our view, this and other works build up compelling
evidence for the prognostic and predictive role of vascular
invasion in nonseminoma patients. The stage is set, then, for
establishing a proper prospective study on this matter, mak-
ing use of a large, multicenter cohort of stage I nonseminoma
patients to be differentially enrolled either in surveillance or
adjuvant treatment according to vascular invasion scoring
and characterization by immunohistochemistry. If the com-
bined invasion of blood vessels and lymph vessels is con-
firmed in future prospective studies as a poor prognostic sign,
we believe a recommendation for routinely performing these
markers should be made.
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